Table 3.
Specific Clinical Data of 11 Patients With JGCTs
| No. | Sex/Age, y | Duration of HTN, mo | BPmax, mm Hg | Antihypertension Drugs | Treatment Effect, mm Hg | Serum Potassium, mmol/L | PRA, ng/mL*h (Upright) | PAC, ng/dL (Upright) | Tumor Diameter, mm | Other Imaging | Follow‐Up, mo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F/26 | 4 | 200/110 | C | 130/90 | 3.9 | 0.30 | 15.20 | 20 | NA | 54 |
| 2 | F/15 | 13 | 245/135 | ABC | 120/80 | 2.5 | 3.50 | 27.00 | 12 | 18FDG‐PET | 33 |
| 3 | F/72 | 36 | NA | AB | 130/80 | 3.8 | NA | NA | 30 | NA | 57 |
| 4 | M/16 | 24 | 220/140 | AB | 135/85 | 3.0 | >12 | 15.77 | 26 | NA | 6 |
| 5 | F/18 | 1 | 240/130 | ABC | 135/90 | 3.8 | >12 | 20.00 | 46 | SRS | NA |
| 6 | F/37 | 84 | 200/140 | ACS | 140/100 | 3.0 | >12 | 27.23 | 40 | SRS | 4 |
| 7 | M/46 | 72 | NA | B | 130/90 | 3.5 | NA | NA | 18 | 18FDG‐PET | 11 |
| 8 | M/10 | 24 | 209/180 | ABC | 140/100 | 2.8 | >12 | 19.67 | 12 | NA | NA |
| 9 | M/40 | 144 | NA | BC | 130/90 | 3.8 | NA | NA | 15 | NA | 4 |
| 10 | F/29 | 0.5 | 180/145 | ABC | 145/100 | 2.5 | 6.17 | 36.84 | 12 | NA | 27 |
| 11 | M/39 | 132 | 180/120 | AC | 145/95 | 2.7 | 18.00 | 49.5 | 13 | NA | 18 |
Abbreviations: A, angiotensin‐converting enzyme inhibitor or angiotensin II receptor antagonist; B, β receptor antagonist; BPmax, maximum blood pressure; C, calcium channel blocker; F, female; FDG‐PET, fluorodeoxyglucose–positron emission tomography; HTN, hypertension; M, male; NA, not available; PAC, plasma aldosterone concentration; PRA, plasma renin activity; S, spironolactone; SRS, somatostatin receptor scintigraphy.